Show Me the Money? Show Us the Data!

How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers? The merits and cautions of data sharing have long been a topic of lively debate in the research community, but in...

Online Exclusives

Treatment at Higher-Volume Myeloma Centers Is Associated With Lower Mortality

Author’s Perspective Ronald S. Go, MD, lead author: “Our research shows that, for rare cancers such as myeloma, it may be beneficial to either refer...

Public Comment Period for Clinical Practice Guidelines on Catastrophic Antiphospholipid Syndrome

The European RARE-Bestpractices project in collaboration with the McMaster University GRADE Center is developing a clinical practice guideline on the diagnosis and management of...

News

From the Blood Journals

WIB_icon

Predicting Response and Prognosis With Midostaurin in Advanced Systemic Mastocytosis

In April 2017, the U.S. Food and Drug Administration approved the multitargeted KIT inhibitor for the treatment of adult patients with FLT3-positive, newly diagnosed...
WIB_icon

Pembrolizumab Prompts Response in Patients With Richter’s Transformation

Patients with chronic lymphocytic leukemia (CLL) who progress early during ibrutinib treatment often develop Richter’s transformation (RT), which is associated with an average survival...

Latest Videos

video

Stephen M. Ansell, MD, PhD: Nivolumab Moves to Hematology

Dr. Ansell, a speaker in the Special Education Session on Newly Approved Drugs, discusses the growing role of nivolumab in hematologic malignancies.
video

Eugenia Vicky Asare, MD: Multidisciplinary Care Saves Lives Among Pregnant Women...

Dr. Asare shares how instituting simple protocols and a multidisciplinary approach dramatically reduced the mortality rate of pregnant women with sickle cell disease living...
video

ASP2215 Successfully Inhibits FLT3 in High-Risk AML Patients

Mark J. Levis, MD, PhD, discusses the results of a phase I/II trial of ASP2215, which was shown to potently, selectively, and sustainably inhibit...
video

Kenneth Ataga, MD: Crizanlizumab: A New Option for Managing Sickle Cell-Related...

The first-in-class humanized monoclonal antibody crizanlizumab reduced the rate of sickle cell-related pain crises, compared with placebo. Dr. Ataga discusses results of the SUSTAIN...

On Location

Investigational CAR T-Cell Therapy Improves Objective Response Rate in Patients With Aggressive NHL

At the 2017 AACR Annual Meeting, Frederick L. Locke, MD, from the H. Lee Moffitt...

Investigational Drug TEW-7197 Improves Myeloma Outcomes Both as Single Agent and in Combination With Ixazomib

TGF-β, a multifunctional cytokine, is produced in multiple myeloma (MM) cells and cells in the...

BION-1301 May Improve Survival and Inhibit Treatment Resistance for Patients With Myeloma

In a preclinical study presented at the 2017 AACR Annual Meeting, BION-1301, an anti-human APRIL...

CHRONOS-1: Copanlisib Shows Promise for Patients With Relapsed/Refractory Indolent B-Cell NHL

Patients with relapsed/refractory indolent B-cell lymphomas often have limited options beyond standard therapies once their...

A Tale of Two Proteasome Inhibitors: Carfilzomib Versus Bortezomib in Multiple Myeloma

At the 16th International Myeloma Workshop (IMW), two clinical trials of patients with newly diagnosed...

Denosumab Delays Skeletal-Related Events in Newly Diagnosed Multiple Myeloma

Denosumab (a monoclonal antibody that targets the RANK ligand) was noninferior to zoledronic acid (ZA)...

Latest Headlines

Advertisement

ASH Directions

Marching for Science, New Opportunities for International Collaboration, and more

Marching for Science The first March for Science, which took place Saturday, April 22, 2017, in more than 600 locations around the world, drew hundreds...

Webinar Preview for 2017 ASH Meeting, ASH Global Capacity-Building Showcase, and more

Webinar Preview: Series for the 2017 ASH Meeting on Hematologic Malignancies A special webinar series previewing the 2017 ASH Meeting on Hematologic Malignancies is...

Sign up for our e-Newsletter!

ASH 2017 Bridge Grant Awards, Hematologists Receive Stand Up To Cancer 2017 Innovative Research...

ASH Announces 2017 Bridge Awards The American Society of Hematology (ASH) announced the names of five investigators who have received the latest round of ASH...

ACS Announces Lane W. Adams Quality of Life Award Winners, 2017 Eric G. Neilson,...

ACS Announces Lane W. Adams Quality of Life Award Winners The ACS honored six cancer caregivers with the Lane W. Adams Quality of Life Award,...

Fred Hutch Launches APOLLO Network for the Cancer Moonshot Initiative, University of Arizona to...

Fred Hutchinson Researchers to Assess Protein Assays for the Cancer Moonshot Initiative As part of the Cancer Moonshot initiative, the APOLLO (Applied Proteogenomics Organizational Learning...

Show Me the Money? Show Us the Data!

How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers? The merits and cautions of data sharing have long been a...

Uncommon Presentations, Uncommon Cancers

In this column, Beth Faiman, CNP, PhD, reviews the 5th edition of the Textbook of Uncommon Cancer. Have you read any hematology-related books recently? Let us...

Agent Orange and Hematologic Malignancies: The Fog of War Still Hovers

More than 40 years after the Vietnam War, the fog of Agent Orange hangs thick over veterans and those providing their medical care. Aging...